Your browser doesn't support javascript.
loading
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Noronha, Ashish; Belugali Nataraj, Nishanth; Lee, Joo Sang; Zhitomirsky, Benny; Oren, Yaara; Oster, Sara; Lindzen, Moshit; Mukherjee, Saptaparna; Will, Rainer; Ghosh, Soma; Simoni-Nieves, Arturo; Verma, Aakanksha; Chatterjee, Rishita; Borgoni, Simone; Robinson, Welles; Sinha, Sanju; Brandis, Alexander; Kerr, D Lucas; Wu, Wei; Sekar, Arunachalam; Giri, Suvendu; Chung, Youngmin; Drago-Garcia, Diana; Danysh, Brian P; Lauriola, Mattia; Fiorentino, Michelangelo; Ardizzoni, Andrea; Oren, Moshe; Blakely, Collin M; Ezike, Jideofor; Wiemann, Stefan; Parida, Laxmi; Bivona, Trever G; Aqeilan, Rami I; Brugge, Joan S; Regev, Aviv; Getz, Gad; Ruppin, Eytan; Yarden, Yosef.
Afiliación
  • Noronha A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Belugali Nataraj N; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Lee JS; Cancer Data Science Lab, NCI, NIH, Bethesda, Maryland.
  • Zhitomirsky B; Next-Gen Medicine Lab, School of Medicine and Department of Artificial Intelligence, Sungkyunkwan University, Suwon, Republic of Korea.
  • Oren Y; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Oster S; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Lindzen M; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts.
  • Mukherjee S; Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
  • Will R; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Ghosh S; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Simoni-Nieves A; Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Verma A; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Chatterjee R; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Borgoni S; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Robinson W; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Sinha S; Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Brandis A; Cancer Data Science Lab, NCI, NIH, Bethesda, Maryland.
  • Kerr DL; Cancer Data Science Lab, NCI, NIH, Bethesda, Maryland.
  • Wu W; Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Sekar A; Department of Medicine, University of California, San Francisco, California.
  • Giri S; Department of Medicine, University of California, San Francisco, California.
  • Chung Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Drago-Garcia D; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Danysh BP; Next-Gen Medicine Lab, School of Medicine and Department of Artificial Intelligence, Sungkyunkwan University, Suwon, Republic of Korea.
  • Lauriola M; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Fiorentino M; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Ardizzoni A; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
  • Oren M; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
  • Blakely CM; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
  • Ezike J; Medical Oncology IRCCS Azienda Ospedaliero, University of Bologna, Bologna, Italy.
  • Wiemann S; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Parida L; Department of Medicine, University of California, San Francisco, California.
  • Bivona TG; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
  • Aqeilan RI; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Brugge JS; Computational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Regev A; Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Getz G; Thomas J. Watson Research Center, IBM Research, Yorktown Heights, New York.
  • Ruppin E; Department of Medicine, University of California, San Francisco, California.
  • Yarden Y; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Cancer Discov ; 12(11): 2666-2683, 2022 11 02.
Article en En | MEDLINE | ID: mdl-35895872
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas / Proteínas Tirosina Quinasas Receptoras / Resistencia a Antineoplásicos / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article País de afiliación: Israel
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas / Proteínas Tirosina Quinasas Receptoras / Resistencia a Antineoplásicos / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article País de afiliación: Israel